Seeking Alpha

Y-mAbs Therapeutics: The Next Deal Showcases The Value And Challenges Of Biotech M&A

I'm on the record as an optimist for Y-mAbs Therapeutics, Inc. (YMAB), with particular enthusiasm for what I was seeing with their modular SADA platform. To date, that enthusiasm hasn't really borne ...
Seeking Alpha

Y-mAbs Therapeutics: Slow But Steady Prospect In Rare Cancers

Y-mAbs Therapeutics' naxitamab is approved for R/R High-Risk Neuroblastoma, with ongoing trials to expand its use, but the market size is limited. Financially, YMAB has a market cap of $644 million ...